Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 14, Number 11—November 2008

Research

Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany

Barbara Eker, Johannes Ortmann, Giovanni B. Migliori, Giovanni Sotgiu, Ralf Muetterlein, Rosella Centis, Harald Hoffmann, Detlef Kirsten, Tom Schaberg, Sabine Ruesch-Gerdes, Christoph LangeComments to Author , and for the German TBNET Group
Author affiliations: Research Center Borstel, Borstel, Germany (B. Eker, S. Ruesch-Gerdes, C. Lange); Karl-Hansen-Clinic, Bad Lippspringe, Germany (J. Ortmann); World Health Organization Collaborating Center for TB and Lung Diseases, Tradate, Italy (G.B. Migliori, R. Centis); Sassari University, Sassari, Italy (G. Sotgiu); Regional Hospital, Pasberg, Germany (R. Muetterlein); Asklepios-Hospital, Gauting, Germany (H. Hoffmann); Hospital Großhansdorf, Großhansdorf, Germany (D. Kirsten); Deakoness Hospital, Rotenburg, Germany (T. Schaberg);

Main Article

Table 4

TB treatment outcomes in study patients treated with linezolid compared with those not treated with linezolid*

Treatment outcomes No. (%) patients treated with linezolid, n = 74 No. (%) patients not treated with linezolid, n = 110 p value 95% CI
Cured 21 (28.4) 61 (55.5) 0.0003† −0.41 to −0.13
Completed 12 (16.2) 15 (13.6) 0.56 −0.07 to 0.13
Successful treatment (cured + completed) 33 (44.6) 76 (69.1) 0.0007† −0.39 to −0.1
Died 8 (10.8) 7 (6.4) 0.31 −0.04 to 0.12
Failure 1 (1.4)
Treatment failure (death or failure) 9 (12.2) 7 (6.4) 0.15 −0.02 to 0.14
Default 1 (0.9)
Transferred out 10 (13.5) 15 (13.6) 0.98 −0.1 to 0.09
Uncertain outcome (default + transferred out) 10 (13.5) 16 (14.5) 0.84 −0.11 to 0.09
Still on treatment 22 (29.7) 11 (10) 0.0009† 0.07 to 0.3

*TB, tuberculosis; CI, confidence interval.
†Significant result (p<0.05).

Main Article

1Additional German Tuberculosis Network European Trials group (TBNET) contributors: R. Eberhardt, Thorax-Clinic-Heidelberg, Heidelberg; A. Esselmann, Pulmonary Clinic, Hemer; H. Flick, Charité, Berlin; M. Hamm, Hospital Diekholzen, Diekholzen; P. Hammerl, Hospital Immenhausen, Immenhausen; H. Hang, Hospital Schillerhöhe, Schillerhöhe; P. Hannemann, Deakoness Hospital, Neustadt; D. Hillemann, Research Center Borstel, Borstel; B. Kretz, Asklepios Hospital, Gauting; C. Laumanns, Bethania Hospital, Solingen; G. Liebetrau, Lostau Hospital, Lostau; S. Ott, Helios Clinic Emil von Behring, Berlin; A. Paulick, Pulmonary Clinic-Coswig, Coswig; M.W. Pletz, Hannover Medical School, Hannover; M. Rau, Pulmonary Clinic, Wangen; G. Rohde, Bergmannsheil Hospital, Bochum; A. de Roux, Evangelische Lungenklinik, Berlin; C. Schaudt, Hospital St. Blasien, St. Blasien; K-D.Schneider, Pulmonary Clinic, Hannover-East, Hannover; S. Stenger, University Hospital, Ulm; D. Wagner, University Hospital, Freiburg; and T. Wolf, University Hospital, Frankfurt.

TOP